Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients.
Russell B, Moss CL, Palmer K, Sylva R, D'Souza A, Wylie H, Haire A, Cahill F, Steel R, Hoyes A, Wilson I, Macneil A, Shifa B, Monroy-Iglesias MJ, Papa S, Irshad S, Ross P, Spicer J, Kordasti S, Crawley D, Zaki K, Sita-Lumsden A, Josephs D, Enting D, Swampillai A, Sawyer E, Fields P, Wrench D, Rigg A, Sullivan R, Van Hemelrijck M, Dolly S. Russell B, et al. Among authors: wrench d. Cancers (Basel). 2021 May 19;13(10):2479. doi: 10.3390/cancers13102479. Cancers (Basel). 2021. PMID: 34069565 Free PMC article.
Assessing risk and improving survival in lymphoma.
Fields PA, Wrench DJ. Fields PA, et al. Br J Gen Pract. 2015 May;65(634):220-1. doi: 10.3399/bjgp15X684661. Br J Gen Pract. 2015. PMID: 25918305 Free PMC article. No abstract available.
Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London.
Russell B, Moss C, Papa S, Irshad S, Ross P, Spicer J, Kordasti S, Crawley D, Wylie H, Cahill F, Haire A, Zaki K, Rahman F, Sita-Lumsden A, Josephs D, Enting D, Lei M, Ghosh S, Harrison C, Swampillai A, Sawyer E, D'Souza A, Gomberg S, Fields P, Wrench D, Raj K, Gleeson M, Bailey K, Dillon R, Streetly M, Rigg A, Sullivan R, Dolly S, Van Hemelrijck M. Russell B, et al. Among authors: wrench d. Front Oncol. 2020 Jul 22;10:1279. doi: 10.3389/fonc.2020.01279. eCollection 2020. Front Oncol. 2020. PMID: 32903324 Free PMC article.
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.
Russell B, Moss CL, Shah V, Ko TK, Palmer K, Sylva R, George G, Monroy-Iglesias MJ, Patten P, Ceesay MM, Benjamin R, Potter V, Pagliuca A, Papa S, Irshad S, Ross P, Spicer J, Kordasti S, Crawley D, Wylie H, Cahill F, Haire A, Zaki K, Sita-Lumsden A, Josephs D, Enting D, Swampillai A, Sawyer E, D'Souza A, Gomberg S, Harrison C, Fields P, Wrench D, Rigg A, Sullivan R, Kulasekararaj A; Guy’s Cancer Real World Evidence; Dolly S, Van Hemelrijck M. Russell B, et al. Among authors: wrench d. Br J Cancer. 2021 Sep;125(7):939-947. doi: 10.1038/s41416-021-01500-z. Epub 2021 Aug 16. Br J Cancer. 2021. PMID: 34400804 Free PMC article.
Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
Booth S, Curley HM, Varnai C, Arnold R, Lee LYW, Campton NA, Cook G, Purshouse K, Aries J, Innes A, Cook LB, Tomkins O, Oram HS, Tilby M, Kulasekararaj A, Wrench D, Dolly S, Newsom-Davies T, Pettengell R, Gault A, Moody S, Mittal S, Altohami M, Tillet T, Illingworth J, Mukherjee L, Apperly J, Ashcroft J, Rabin N, Carmichael J, Cazier JB, Kerr R, Middleton G, Collins GP, Palles C; UKCCMP team. Booth S, et al. Among authors: wrench d. Br J Haematol. 2022 Feb;196(4):892-901. doi: 10.1111/bjh.17937. Epub 2021 Nov 10. Br J Haematol. 2022. PMID: 34761389 Free PMC article.
Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
Dhanapal V, Gunasekara M, Lianwea C, Marcus R, De Lord C, Bowcock S, Devereux S, Patten P, Yallop D, Wrench D, Fields P, Kassam S. Dhanapal V, et al. Among authors: wrench d. Leuk Lymphoma. 2017 Sep;58(9):1-9. doi: 10.1080/10428194.2016.1276288. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28093003
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
Eyre TA, Hildyard C, Hamblin A, Ali AS, Houlton A, Hopkins L, Royston D, Linton KM, Pettitt A, Rule S, Cwynarski K, Barrington SF, Warbey V, Wrench D, Barrans S, Hirst CS, Panchal A, Roudier MP, Harrington EA, Davies A, Collins GP. Eyre TA, et al. Among authors: wrench d. Hematol Oncol. 2019 Oct;37(4):352-359. doi: 10.1002/hon.2662. Epub 2019 Sep 9. Hematol Oncol. 2019. PMID: 31385336 Clinical Trial.
38 results